BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25919760)

  • 21. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.
    Manasa J; Varghese V; Pond SLK; Rhee SY; Tzou PL; Fessel WJ; Jang KS; White E; Rögnvaldsson T; Katzenstein DA; Shafer RW
    Sci Rep; 2017 Sep; 7(1):11559. PubMed ID: 28912582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
    Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
    PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
    Blanch-Lombarte O; Santos JR; Peña R; Jiménez-Moyano E; Clotet B; Paredes R; Prado JG
    J Antimicrob Chemother; 2020 Sep; 75(9):2535-2546. PubMed ID: 32556165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
    Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
    Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
    McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
    Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
    mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.
    Knops E; Kemper I; Schülter E; Pfister H; Kaiser R; Verheyen J
    AIDS; 2010 Mar; 24(5):779-81. PubMed ID: 20139751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.
    Sutherland KA; Goodall RL; McCormick A; Kapaata A; Lyagoba F; Kaleebu P; Thiltgen G; Gilks CF; Spyer M; Kityo C; Pillay D; Dunn D; Gupta RK; ;
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1032-7. PubMed ID: 26258548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
    J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease.
    Flynn WF; Chang MW; Tan Z; Oliveira G; Yuan J; Okulicz JF; Torbett BE; Levy RM
    PLoS Comput Biol; 2015 Apr; 11(4):e1004249. PubMed ID: 25894830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
    Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
    AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.
    Sakai K; Chikata T; Brumme ZL; Brumme CJ; Gatanaga H; Oka S; Takiguchi M
    Retrovirology; 2015 Nov; 12():98. PubMed ID: 26585907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs.
    Su CT; Koh DW; Gan SK
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31489889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.